Abstract: This invention relates to methods of prophylactically or therapeutically treating viral infections particularly in the lower respiratory tract. Treatment of coronavirus infections is particularly contemplated. The invention also relates to the use of BLIS-producing Streptococcus strains, extracts and exudates thereof, and compositions containing same in the prevention, reduction, or treatment of such virus infections.
Type:
Application
Filed:
March 31, 2021
Publication date:
September 28, 2023
Applicant:
BLIS TECHNOLOGIES LIMITED
Inventors:
John David Francis Hale, John Robert Tagg
Abstract: This invention relates to Micrococcus luteus containing compositions useful for controlling skin disorders in which bacteria are a causative component. The invention also provides for a new strain of Micrococcus luteus useful in these compositions.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
October 9, 2012
Assignee:
Blis Technologies Limited
Inventors:
John Robert Tagg, Christopher Norman Chilcott, Mohammed Abdullah Ali Alqumber
Abstract: This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
November 15, 2011
Assignee:
Blis Technologies Limited
Inventors:
John Robert Tagg, Christopher Norman Chilcott, Jeremy Paul Burton
Abstract: This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis.
Type:
Grant
Filed:
July 19, 2004
Date of Patent:
September 29, 2009
Assignee:
BLIS Technologies Limited
Inventors:
John Robert Tagg, Christopher Norman Chilcott, Jeremy Paul Burton
Abstract: This invention provides novel Streptococcus salivarius, compositions containing same, and use of S. salivarius strains as antimicrobial agents. The strains are bacterial inhibitors with respect to at least S. mutans and/or MS and therefore have a number of therapeutic applications. The applications include but are not limited to forming part of therapeutic formulations for use in controlling, treating, or preventing dental caries.
Type:
Grant
Filed:
February 21, 2003
Date of Patent:
June 5, 2007
Assignee:
BLIS Technologies Limited
Inventors:
Christopher Norman Chilcott, John Robert Tagg
Abstract: This invention provides an antibacterial protein, Salivaricin B. Salivaricin B is bacteriocidal with respect to, inter alia, S. pyogenes and therefore has numerous therapeutic applications. These applications include, but are not limited to, forming part of therapeutic formulations for use in treating or preventing streptococcal infections of the throat.
Type:
Grant
Filed:
December 21, 2001
Date of Patent:
August 10, 2004
Assignees:
University of Otago, Blis Technologies Limited
Inventors:
John Robert Tagg, Karen Patricia Dierksen, Mathew Upton